Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.71 |
| ▸ | KDM1A | O60341 | 11/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.54 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478510 | 1.00 | ENPP1 (0.71) | ENPP1KDM1AKDRFLT1EGFR | |
| Hydrochloric Acid SCHEMBL8307436 | 0.98 | ENPP1 (0.69) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL30053845 | 0.95 | ENPP1 (0.79) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL1011724 | 0.95 | ENPP1 (0.79) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL1010156 | 0.95 | ENPP1 (0.79) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL1507495 | 0.94 | ENPP1 (0.64) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL1507551 | 0.94 | ENPP1 (0.64) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL28412498 | 0.93 | ENPP1 (0.63) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL28407634 | 0.93 | ENPP1 (0.63) | ENPP1KDM1AKDRFLT1EGFR | |
| SCHEMBL4373681 | 0.92 | ENPP1 (0.73) | ENPP1KDM1AKDRFLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108999-B | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2023-11-03 | — | — | CN | claimed |
| CN-115108999-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2022-09-27 | — | — | CN | claimed |
| CN-113912554-A | Erlotinib hydrochloride synthesis and refining process | 湖北一半天制药有限公司 | 2022-01-11 | — | — | CN | claimed |
| WO-2021017996-A1 | PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 暨南大学 | 2021-02-04 | — | — | WO | claimed |
| CN-112300082-A | Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application | 暨南大学 | 2021-02-02 | — | — | CN | claimed |
| EP-2433931-B2 | New method for the preparation of erlotinib | ITALIANA SINT SPA (IT) | 2016-11-02 | — | — | EP | claimed |
| US-9340515-B2 | Pure erlotinib | GENERICS (UK) LIMITED (GB) | 2016-05-17 | — | — | US | claimed |
| CN-104945332-A | Preparation method of erlotinib | GUANGZHOU INST BIOMED & HEALTH | 2015-09-30 | — | — | CN | claimed |
| EP-2139868-B1 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LTD (IN) | 2015-07-29 | — | — | EP | claimed |
| CN-104725327-A | Environment-friendly method for preparing high-yield erlotinib hydrochloride | UNIV SHANDONG | 2015-06-24 | — | — | CN | claimed |
| EP-2162444-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | Hetero Drugs Limited (IN) | 2010-03-17 | — | — | EP | claimed |
| EP-2139868-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Cipla Limited (IN) | 2010-01-06 | — | — | EP | claimed |
| EP-1110953-B1 | Quinazoline derivatives | PFIZER PROD INC (US) | 2009-10-28 | — | — | EP | claimed |
| US-20090131665-A1 | Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI | PLUS CHEMICALS S.A. (CH) | 2009-05-21 | — | — | US | claimed |
| WO-2009025873-A2 | PROCESSES FOR THE PREPARATION OF CRYSTALLINE FORMS A, B AND PURE CRYSTALLINE FORM A OF ERLOTINIB HCL | PLUS CHEMICALS SA (CH) | 2009-02-26 | — | — | WO | claimed |
| WO-2009007984-A2 | AN IMPROVED PROCESS FOR ERLOTINIB HYDROCHLORIDE | HETERO DRUGS LIMITED (IN) | 2009-01-15 | — | — | WO | claimed |
| US-20090012295-A1 | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib | PLUS CHEMICALS SA (CH) | 2009-01-08 | — | — | US | claimed |
| WO-2009002538-A2 | AMORPHOUS ERLOTINIB, PROCESSES FOR THE PREPARATION THEREOF, AND PROCESSES TO PREPARE ADDITIONAL FORMS OF ERLOTINIB | PLUS CHEMICALS S.A. (CH) | 2008-12-31 | — | — | WO | claimed |
| WO-2008122776-A2 | PROCESS FOR PREPARATION OF ERLOTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | CIPLA LIMITED (IN) | 2008-10-16 | — | — | WO | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131665-A1 | Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI | EGFR, NRAS, HRAS | ENPP1 2043/4885KDM1A 4266/4885KDR 188/4885 |
| US-20090012295-A1 | Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib | KRAS, EGFR, ABL1 | ENPP1 1692/4885KDM1A 4187/4885KDR 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.